Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
33.62
-1.74 (-4.92%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Revolution Medicines Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Cash & Equivalents | 543.06 | 696.15 | 161.41 | 108.5 | 104.27 | Upgrade
|
| Short-Term Investments | 1,746 | 1,157 | 483.53 | 468.56 | 336.47 | Upgrade
|
| Cash & Short-Term Investments | 2,289 | 1,853 | 644.94 | 577.05 | 440.74 | Upgrade
|
| Cash Growth | 23.55% | 187.31% | 11.77% | 30.93% | 259.03% | Upgrade
|
| Receivables | - | 1.25 | 4.67 | 5.93 | 6.39 | Upgrade
|
| Prepaid Expenses | 38.33 | 25.07 | 10.57 | 6.79 | 6.99 | Upgrade
|
| Total Current Assets | 2,328 | 1,879 | 660.19 | 589.77 | 454.12 | Upgrade
|
| Property, Plant & Equipment | 141.82 | 100.01 | 73.74 | 71.24 | 36.34 | Upgrade
|
| Goodwill | 14.61 | 14.61 | 14.61 | 14.61 | 14.61 | Upgrade
|
| Other Intangible Assets | 56.67 | 57.74 | 58.81 | 59.88 | 60.95 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | 0.5 | - | Upgrade
|
| Other Long-Term Assets | 17.57 | 10.06 | 4.59 | 2 | 1.39 | Upgrade
|
| Total Assets | 2,558 | 2,062 | 811.93 | 737.99 | 567.4 | Upgrade
|
| Accounts Payable | 54.43 | 61.79 | 21.31 | 14.06 | 12.61 | Upgrade
|
| Accrued Expenses | 96.03 | 70.8 | 28.94 | 27.41 | 18.69 | Upgrade
|
| Current Portion of Leases | 12.87 | 7.37 | 6.77 | 6.21 | 3.67 | Upgrade
|
| Current Unearned Revenue | - | - | 4.46 | 12.36 | 12.11 | Upgrade
|
| Other Current Liabilities | 0.58 | 3.9 | 0.51 | 0.31 | 0.1 | Upgrade
|
| Total Current Liabilities | 163.91 | 143.85 | 61.98 | 60.35 | 47.18 | Upgrade
|
| Long-Term Leases | 122.97 | 80.58 | 57.43 | 60.42 | 28.99 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 6.57 | 8.48 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 2.35 | 3.12 | 7.03 | 7.44 | 7.44 | Upgrade
|
| Other Long-Term Liabilities | 3.86 | 7.97 | 0.3 | 0.63 | 0.63 | Upgrade
|
| Total Liabilities | 293.1 | 235.51 | 126.74 | 135.42 | 92.73 | Upgrade
|
| Common Stock | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 4,002 | 2,963 | 1,388 | 1,056 | 740.1 | Upgrade
|
| Retained Earnings | -1,738 | -1,138 | -701.34 | -452.64 | -265.55 | Upgrade
|
| Comprehensive Income & Other | 1.32 | 0.54 | -1.78 | -0.38 | 0.12 | Upgrade
|
| Total Common Equity | 2,265 | 1,826 | 685.19 | 602.57 | 474.68 | Upgrade
|
| Shareholders' Equity | 2,265 | 1,826 | 685.19 | 602.57 | 474.68 | Upgrade
|
| Total Liabilities & Equity | 2,558 | 2,062 | 811.93 | 737.99 | 567.4 | Upgrade
|
| Total Debt | 135.84 | 87.94 | 64.21 | 66.63 | 32.66 | Upgrade
|
| Net Cash (Debt) | 2,153 | 1,765 | 580.74 | 510.42 | 408.08 | Upgrade
|
| Net Cash Growth | 22.01% | 203.93% | 13.78% | 25.08% | 232.97% | Upgrade
|
| Net Cash Per Share | 12.84 | 15.60 | 7.20 | 7.01 | 7.44 | Upgrade
|
| Filing Date Shares Outstanding | 185.91 | 164.69 | 90.49 | 74.19 | 73.38 | Upgrade
|
| Total Common Shares Outstanding | 185.9 | 164.67 | 90.41 | 74.14 | 66.6 | Upgrade
|
| Working Capital | 2,164 | 1,735 | 598.2 | 529.42 | 406.95 | Upgrade
|
| Book Value Per Share | 12.19 | 11.09 | 7.58 | 8.13 | 7.13 | Upgrade
|
| Tangible Book Value | 2,194 | 1,754 | 611.77 | 528.08 | 399.12 | Upgrade
|
| Tangible Book Value Per Share | 11.80 | 10.65 | 6.77 | 7.12 | 5.99 | Upgrade
|
| Machinery | 31.44 | 28.09 | 21.74 | 14.98 | 11.6 | Upgrade
|
| Construction In Progress | 0.39 | 0.51 | - | 0.13 | 1.98 | Upgrade
|
| Leasehold Improvements | 14.28 | 11.95 | 11.4 | 7.25 | 3.39 | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.